Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vigil Neuroscience Inc (VIGL)
NASDAQ:VIGL
Holding VIGL?
Track your performance easily
VIGL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.49 - $6.06
Previous CloseN/A
Volume101.11K
Average Volume (3M)319.41K
Market Cap
$77.26M
Enterprise Value$39.87M
Total Cash (Recent Filing)$24.15M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Mar 20, 2025EPS Estimate
-0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.07
Shares Outstanding40,879,486
10 Day Avg. Volume248,059
30 Day Avg. Volume319,414
Standard Deviation0.38
R-Squared0.05
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)4.50
P/FCF Ratio4.50
Enterprise Value/Market Cap0.52
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.45
Forecast
1Y Price Target
$14.53Price Target Upside652.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Vigil Neuroscience Inc News
PremiumCompany Announcements
Vigil Neuroscience Advances Key Clinical Programs
PremiumCompany Announcements
Vigil Neuroscience Advances Alzheimer’s Trial, Eyes 2025 Data
Bulls Say, Bears Say
Bulls Say
Innovative Drug DevelopmentVigil is developing a unique TREM2-targeting therapeutics pipeline to treat both rare and highly prevalent degenerative disorders.
Regulatory OpportunitiesThe FDA indicated that it is open to an accelerated approval pathway pending additional data, and analysts see blockbuster revenue potential if ultimately approved, as iluzanebart is the only potential treatment in clinical-stage testing.
Strategic CollaborationThe collaboration between GlaxoSmithKline and Muna Therapeutics is seen as a validation of VIGL's approach, providing an incremental positive for the company.
Bears Say
Clinical RiskVIGL shares slipped 6-7% due to negative top-line data from Alector for its TREM2-targeting antibody in Alzheimer's disease.
Market SentimentThere is likely near-term negative sentiment on the TREM2 target, therefore, weakness in VIGL shares is anticipated.
ValuationThere has been a significant drop in VIGL's valuation following negative TREM2 data from a competitor.
---
VIGL FAQ
What was Vigil Neuroscience Inc’s price range in the past 12 months?
Vigil Neuroscience Inc lowest stock price was $1.49 and its highest was $6.06 in the past 12 months.
What is Vigil Neuroscience Inc’s market cap?
Vigil Neuroscience Inc’s market cap is $77.26M.
When is Vigil Neuroscience Inc’s upcoming earnings report date?
Vigil Neuroscience Inc’s upcoming earnings report date is Mar 20, 2025 which is in 58 days.
How were Vigil Neuroscience Inc’s earnings last quarter?
Vigil Neuroscience Inc released its earnings results on Nov 07, 2024. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.545 by $0.075.
Is Vigil Neuroscience Inc overvalued?
According to Wall Street analysts Vigil Neuroscience Inc’s price is currently Undervalued.
Does Vigil Neuroscience Inc pay dividends?
Vigil Neuroscience Inc does not currently pay dividends.
What is Vigil Neuroscience Inc’s EPS estimate?
Vigil Neuroscience Inc’s EPS estimate is -0.54.
How many shares outstanding does Vigil Neuroscience Inc have?
Vigil Neuroscience Inc has 40,879,486 shares outstanding.
What happened to Vigil Neuroscience Inc’s price movement after its last earnings report?
Vigil Neuroscience Inc reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.545. Following the earnings report the stock price went down -6.299%.
Which hedge fund is a major shareholder of Vigil Neuroscience Inc?
Currently, no hedge funds are holding shares in VIGL
---
Vigil Neuroscience Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.53 (652.85% Upside)
$14.53 (652.85% Upside)
Blogger Sentiment
Bullish
VIGL Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 56.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $49.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.66%
12-Months-Change
Fundamentals
Return on Equity
-73.62%
Trailing 12-Months
Asset Growth
-17.52%
Trailing 12-Months
Company Description
Vigil Neuroscience Inc
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families.
---
VIGL Stock 12 Month Forecast
Average Price Target
$14.53
▲(652.85% Upside)
Technical Analysis
Annovis Bio
―
Anavex Life Sciences
―
Inmune Bio
―
Cassava Sciences
―
SELLAS Life Sciences Group
―
BioMarin Pharmaceutical
―
Best Analysts Covering VIGL
1 Year
1 Year Success Rate
0/12 ratings generated profit
1 Year Average Return
-44.00%
reiterated a buy rating 2 months ago
Copying Jason Butler's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -44.00% per trade.
---